Cell therapy for steroid-resistant graft-versus-host disease
Part of Immune system & allergy clinical trials.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old (the first few people in the study must be 18 or older).
- You must have moderate to severe acute graft-versus-host disease (GVHD), which is a complication after a stem cell transplant.
- Your GVHD must not have improved with steroid treatment (this is called steroid-refractory GVHD).
- You must not have received any other treatment for GVHD besides steroids.
- If you are a woman who can become pregnant, you must have a negative pregnancy test and agree to use contraception.
- You must be willing to follow the study procedures and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This study tests an experimental cell therapy called VUM02 for people who have graft-versus-host disease (GvHD) after a stem cell transplant that hasn't improved with standard steroid treatment. The goal is to see if this new treatment can help control GvHD symptoms and improve outcomes.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
This trial tests a new cell therapy called CNK-UT for people with severe graft-versus-host disease (aGVHD) that hasn't improved with steroid treatment after a stem cell transplant. The goal is to see if it can help control the immune reaction.
Hear when a new Steroid Refractory Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.